In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

How Immuno-Oncology Is Turning Biomarker Development On Its Head

Executive Summary

Immuno-oncology’s challenge is to orchestrate a biomarker program in a highly competitive drug development landscape knowing that prior to having significant clinical experience, the program is unlikely to yield the kinds of binary measurements used to define and select a patient population for a targeted therapy.


Related Content

Diagnostics In 2016: From Alere To Zika
Bristol Pushes Pedal To Metal In Immuno-Oncology Combo Testing
Roche's Guide To Success In Oncology
FDA, PD-1 Inhibitor Sponsors Discussing Real-World Study
Which Path Forward For Foundation Medicine?
Industry, Cancer Groups Draft Blueprint For PD-1 Companion Dx Approvals
Immunotherapy: Big Pharma’s Seductive Embrace


Related Companies

Related Deals